GlycoMimetics to Report First Quarter Financial Results on May 1, 2020
The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 4567397. A webcast replay will be available via the “Investors” tab on the
We encourage speakers and participants to connect early to ensure that all callers are able to connect. Perhaps, include language in earnings announcement and release to remind all speakers/participants to dial in 15 minutes prior to the call start time. Also, any callers who would like to ask questions, to queue early in the call.
This press release contains forward-looking statements regarding the Company’s strategy and the clinical development and potential benefits and impact of its drug candidates. These forward-looking statements include those relating to the planned clinical development of the Company’s product candidates, including expectations with regard to the enrollment of patients in its ongoing Phase 3 clinical trial, and its other plans for its current cash resources. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing